What is AvoMD?
AvoMD operates as a sophisticated AI platform designed to empower healthcare enterprises by embedding trusted clinical knowledge directly into the point-of-care environment. By synthesizing medical guidelines, payer-specific requirements, and real-time patient data from Electronic Health Records (EHR), the platform functions as a clinical copilot. This technology automates critical administrative and clinical tasks, including documentation improvement, discharge planning, and order management. By transforming static EHR systems into dynamic, intelligent systems of action, AvoMD addresses the dual challenges of clinician burnout and operational inefficiency, ensuring that evidence-based care is delivered with precision and speed.
How much funding has AvoMD raised?
AvoMD has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2026): $10M with participation from AlleyCorp companies, Las Olas VC, Noro-Moseley Partners, and Medmountain Ventures
Key Investors in AvoMD
AlleyCorp companies
AlleyCorp is a venture builder and investment firm that focuses on creating and scaling transformative businesses by leveraging a network of tech pioneers and entrepreneurs.
Las Olas VC
Las Olas Venture Capital specializes in backing founders who are modernizing outdated business workflows through AI and software applications, with a strong focus on vertical SaaS.
Noro-Moseley Partners
Noro-Moseley Partners is an early growth equity firm that partners with high-growth B2B technology and healthcare companies to drive sustainable economic scaling.
What's next for AvoMD?
With this latest round of financing, AvoMD is poised to scale its operations and deepen its penetration within the enterprise healthcare market. The strategic roadmap focuses on expanding the platform's integration capabilities across diverse EHR architectures and enhancing its automated workflow features. As the company transitions from its current growth phase, the focus will shift toward scaling its deployment to larger health systems, thereby maximizing the impact of its clinical copilots on patient outcomes. The backing from seasoned investors provides not only the necessary liquidity for R&D but also the strategic guidance required to navigate the complex regulatory and operational landscape of the modern healthcare sector.
See full AvoMD company page
